Document is current

Article History

Received: 3 August 2021

Accepted: 9 November 2021

First Online: 1 December 2021

Change Date: 13 May 2022

Change Type: Update

Change Details: Following the original publication of this article, the funding declaration of the article has been corrected with the addition of the following note: Open Access funding enabled and organized by Projekt DEAL.

Declarations

:

: The study was approved by the ethics committee of the Technical University of Munich, Germany (documents no. 1926/2007 and 126/2016S).

: All authors agreed to submission and publication of this article.

: WW has attended Advisory Boards and served as speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK and Molecular Health. WW receives research funding from Roche, MSD, BMS and AstraZeneca, all outside the submitted work; JTS reports the following disclosures: Bristol Myers Squibb, Celgene, Roche (Research Funding); AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in iTheranostics and Pharma15 (< 3%) and member of the Board of Directors for Pharma15, all outside the submitted work. KS is member of the advisory board of TRIMT and received research funding from Roche, all outside the submitted work. KS has a patent filed for a radiopharmaceutical compound. MS served as speaker and scientific advisor for Roche, MSD and BioNTech.